Učitavanje...
EGFR/ErbB2-Targeting Lapatinib Therapy for Aggressive Prolactinomas
CONTEXT: Approximately 10% to 20% of prolactinomas are resistant to dopamine agonist therapy. The ErbB signaling pathway may drive aggressive prolactinoma behavior. OBJECTIVE: We evaluated lapatinib, an ErbB1-epidermal growth factor receptor (EGFR)/ErbB2 or human EGFR2 (HER2) tyrosine kinase inhibit...
Spremljeno u:
| Izdano u: | J Clin Endocrinol Metab |
|---|---|
| Glavni autori: | , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Oxford University Press
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7823257/ https://ncbi.nlm.nih.gov/pubmed/33150390 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/clinem/dgaa805 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|